抗体偶联药物-话题@MedSci

#抗体偶联药物#

3篇内容 | 2235人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2241985, encodeId=e690224198526, content=广泛期<a href='/topic/show?id=5e2e4e08988' target=_blank style='color:#2F92EE;'>#小细胞肺癌#</a>的标准一线治疗是铂类与<a href='/topic/show?id=c62a268958c' target=_blank style='color:#2F92EE;'>#依托泊苷#</a>，联合PD-L1抑制剂。二线治疗则是<a href='/topic/show?id=1c855620260' target=_blank style='color:#2F92EE;'>#拓扑替康#</a>和<a href='/topic/show?id=aef712222ee9' target=_blank style='color:#2F92EE;'>#鲁比奈克汀#</a>。二线治疗的中位无进展生存时间为3.5个月。 <a href='/topic/show?id=85de5518160' target=_blank style='color:#2F92EE;'>#抗体偶联药物#</a><a href='/topic/show?id=174e1222167d' target=_blank style='color:#2F92EE;'>#ABBV-011#</a>是针对SEZ6的抗体偶联药，总体的治疗缓解率为25%，也就是25%的患者肿瘤病灶缩小超过30%，中位缓解持续时间为4.2个月，中位无进展生存时间为3.5个月。从这里来看ABBV-011仍然没有什么突破性进展，后续2，3期临床还能否达到这样的效果，还不好说。总的一句话，小细胞肺癌，真的太难太难。, objectTitle=治疗小细胞肺癌的抗体偶联药ABBV-011，首次人体临床试验结果公布了！, objectType=article, longId=852947, objectId=c38885294edf, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240709/1720491961813_92910.png, objectUrl=/article/show_article.do?id=c38885294edf, replyNumber=0, likeNumber=2, createdTime=8小时前, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=c38885294edf, moduleTitle=治疗小细胞肺癌的抗体偶联药ABBV-011，首次人体临床试验结果公布了！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c38885294edf)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=2240575, encodeId=34aa22405e592, content=<a href='/topic/show?id=85de5518160' target=_blank style='color:#2F92EE;'>#抗体偶联药物#</a> <a href='/topic/show?id=434412081812' target=_blank style='color:#2F92EE;'>#双特异性抗体偶联药物#</a>, objectTitle=引领未来：双抗ADC的前沿进展, objectType=article, longId=853422, objectId=7ed6853422c5, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240713/1720839427878_5579292.png, objectUrl=/article/show_article.do?id=7ed6853422c5, replyNumber=0, likeNumber=8, createdTime=2024-12-03, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=7ed6853422c5, moduleTitle=引领未来：双抗ADC的前沿进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ed6853422c5)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2236665, encodeId=93cf22366651f, content=<a href='/topic/show?id=85de5518160' target=_blank style='color:#2F92EE;'>#抗体偶联药物#</a>, objectTitle=【今日分享】抗体偶联药物分段生产试点注册申报技术要求, objectType=article, longId=850995, objectId=e24285099594, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20241113/1731465060020_8538692.png, objectUrl=/article/show_article.do?id=e24285099594, replyNumber=0, likeNumber=8, createdTime=2024-11-13, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=e24285099594, moduleTitle=【今日分享】抗体偶联药物分段生产试点注册申报技术要求, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e24285099594)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2229540, encodeId=0c012229540fa, content=<a href='/topic/show?id=85de5518160' target=_blank style='color:#2F92EE;'>#抗体偶联药物#</a> <a href='/topic/show?id=6f6c19562f' target=_blank style='color:#2F92EE;'>#ADC#</a> <a href='/topic/show?id=cdc711988903' target=_blank style='color:#2F92EE;'>#有效载荷释放#</a>, objectTitle=ADC连接子的集成设计, objectType=article, longId=845955, objectId=01d48459554f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240826/1724638905319_8538692.png, objectUrl=/article/show_article.do?id=01d48459554f, replyNumber=0, likeNumber=53, createdTime=2024-10-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=01d48459554f, moduleTitle=ADC连接子的集成设计, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=01d48459554f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2226949, encodeId=12a22226949e1, content=<a href='/topic/show?id=85de5518160' target=_blank style='color:#2F92EE;'>#抗体偶联药物#</a> <a href='/topic/show?id=f3b211934582' target=_blank style='color:#2F92EE;'>#靶抗原#</a>, objectTitle=ADC设计中的靶抗原选择, objectType=article, longId=776263, objectId=452ee76263a7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240920/1726828779373_8538692.png, objectUrl=/article/show_article.do?id=452ee76263a7, replyNumber=0, likeNumber=53, createdTime=2024-09-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=452ee76263a7, moduleTitle=ADC设计中的靶抗原选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=452ee76263a7)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2226804, encodeId=4e37222680433, content=<a href='/topic/show?id=85de5518160' target=_blank style='color:#2F92EE;'>#抗体偶联药物#</a> <a href='/topic/show?id=60f111932497' target=_blank style='color:#2F92EE;'>#DP303c#</a>, objectTitle=靶向HER2的抗体偶联药DP303c临床治疗效果首次公布，近70%的实体瘤病情得以控制！, objectType=article, longId=842790, objectId=d753842e90f3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240719/1721369354422_8538692.jpg, objectUrl=/article/show_article.do?id=d753842e90f3, replyNumber=0, likeNumber=53, createdTime=2024-09-20, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d753842e90f3, moduleTitle=靶向HER2的抗体偶联药DP303c临床治疗效果首次公布，近70%的实体瘤病情得以控制！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d753842e90f3)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2226579, encodeId=94c922265e9db, content=<a href='/topic/show?id=85de5518160' target=_blank style='color:#2F92EE;'>#抗体偶联药物#</a> <a href='/topic/show?id=b6b011e87899' target=_blank style='color:#2F92EE;'>#ESMO 2024#</a>, objectTitle=2024ESMO | 新型B7H3抗体偶联药物初次亮相即创多个瘤肿后线疗效新高：张力、赵洪云教授团队口头汇报YL-201初步结果, objectType=article, longId=843769, objectId=3cce843e6950, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240708/1720419680717_92910.jpg, objectUrl=/article/show_article.do?id=3cce843e6950, replyNumber=0, likeNumber=53, createdTime=2024-09-19, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=3cce843e6950, moduleTitle=2024ESMO | 新型B7H3抗体偶联药物初次亮相即创多个瘤肿后线疗效新高：张力、赵洪云教授团队口头汇报YL-201初步结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3cce843e6950)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2217532, encodeId=2da3221e5322d, content=<a href='/topic/show?id=146246308d1' target=_blank style='color:#2F92EE;'>#宫颈癌#</a> <a href='/topic/show?id=85de5518160' target=_blank style='color:#2F92EE;'>#抗体偶联药物#</a> <a href='/topic/show?id=de8811e27587' target=_blank style='color:#2F92EE;'>#Tivdak#</a>, objectTitle=NEJM：4倍缓解几率！创新ADC疗法延长宫颈癌患者生存期, objectType=article, longId=836856, objectId=b791836856b7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240725/1721902488170_8538692.jpg, objectUrl=/article/show_article.do?id=b791836856b7, replyNumber=0, likeNumber=63, createdTime=2024-07-30, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b791836856b7, moduleTitle=NEJM：4倍缓解几率！创新ADC疗法延长宫颈癌患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b791836856b7)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2216490, encodeId=9043221649087, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a> <a href='/topic/show?id=85de5518160' target=_blank style='color:#2F92EE;'>#抗体偶联药物#</a> <a href='/topic/show?id=e6dd29094a1' target=_blank style='color:#2F92EE;'>#免疫疗法#</a>, objectTitle=ADC的联合治疗之路, objectType=article, longId=835251, objectId=0dbd8352513c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240719/1721377067764_92910.png, objectUrl=/article/show_article.do?id=0dbd8352513c, replyNumber=0, likeNumber=0, createdTime=2024-07-23, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=0dbd8352513c, moduleTitle=ADC的联合治疗之路, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0dbd8352513c)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2214739, encodeId=efda2214e3941, content=<a href='/topic/show?id=85de5518160' target=_blank style='color:#2F92EE;'>#抗体偶联药物#</a> <a href='/topic/show?id=bc961088844e' target=_blank style='color:#2F92EE;'>#T-DXd#</a> <a href='/topic/show?id=07fe10530819' target=_blank style='color:#2F92EE;'>#德曲妥珠单抗#</a>, objectTitle=近50%患者3年病情未进展！《自然-医学》：ADC强效抗癌，多种实体瘤效果积极, objectType=article, longId=834273, objectId=1f208342e3d9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240712/1720795549807_1608702.png, objectUrl=/article/show_article.do?id=1f208342e3d9, replyNumber=0, likeNumber=68, createdTime=2024-07-13, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=1f208342e3d9, moduleTitle=近50%患者3年病情未进展！《自然-医学》：ADC强效抗癌，多种实体瘤效果积极, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f208342e3d9)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2210175, encodeId=bc7122101e518, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a> <a href='/topic/show?id=85de5518160' target=_blank style='color:#2F92EE;'>#抗体偶联药物#</a>, objectTitle=《新英格兰医学》治疗案例：年仅45岁的乳腺癌患者病灶转移了，医院做出了怎样的治疗决定？, objectType=article, longId=830399, objectId=b10783039973, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240616/1718524181224_5579292.jpg, objectUrl=/article/show_article.do?id=b10783039973, replyNumber=0, likeNumber=111, createdTime=2024-06-16, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b10783039973, moduleTitle=《新英格兰医学》治疗案例：年仅45岁的乳腺癌患者病灶转移了，医院做出了怎样的治疗决定？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b10783039973)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2209244, encodeId=4e9a220924452, content=<a href='/topic/show?id=85de5518160' target=_blank style='color:#2F92EE;'>#抗体偶联药物#</a> <a href='/topic/show?id=6f6c19562f' target=_blank style='color:#2F92EE;'>#ADC#</a>, objectTitle=ADC的方方面面，你了解多少？, objectType=article, longId=829387, objectId=915382938ef2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240610/1718000912625_5579292.png, objectUrl=/article/show_article.do?id=915382938ef2, replyNumber=0, likeNumber=82, createdTime=2024-06-10, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=915382938ef2, moduleTitle=ADC的方方面面，你了解多少？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=915382938ef2)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2206336, encodeId=c7d222063364b, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a> <a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a> <a href='/topic/show?id=85de5518160' target=_blank style='color:#2F92EE;'>#抗体偶联药物#</a>, objectTitle=权威机构：乳腺癌和肺癌治疗利器！这种疗法或改变肿瘤治疗局面, objectType=article, longId=827152, objectId=997582e152cc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240523/1716475224866_5579292.jpg, objectUrl=/article/show_article.do?id=997582e152cc, replyNumber=0, likeNumber=107, createdTime=2024-05-23, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=997582e152cc, moduleTitle=权威机构：乳腺癌和肺癌治疗利器！这种疗法或改变肿瘤治疗局面, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=997582e152cc)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2205838, encodeId=3bef220583836, content=<a href='/topic/show?id=85de5518160' target=_blank style='color:#2F92EE;'>#抗体偶联药物#</a> <a href='/topic/show?id=6f6c19562f' target=_blank style='color:#2F92EE;'>#ADC#</a> <a href='/topic/show?id=5d3c1146986c' target=_blank style='color:#2F92EE;'>#BsADC#</a>, objectTitle=带你了解双抗ADC, objectType=article, longId=826726, objectId=2fb2826e260d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240520/1716193700965_5579292.png, objectUrl=/article/show_article.do?id=2fb2826e260d, replyNumber=0, likeNumber=88, createdTime=2024-05-21, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=2fb2826e260d, moduleTitle=带你了解双抗ADC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fb2826e260d)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2197754, encodeId=1f3a219e754b8, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a> <a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a> <a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a> <a href='/topic/show?id=85de5518160' target=_blank style='color:#2F92EE;'>#抗体偶联药物#</a> <a href='/topic/show?id=6f6c19562f' target=_blank style='color:#2F92EE;'>#ADC#</a>, objectTitle=超40%患者6个月疾病无进展！周彩存教授：新一代ADC对乳腺癌、肺癌等有效 | 2024 AACR, objectType=article, longId=819548, objectId=05cf81954849, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/conference-with-doctors-in-medical-aprons-PT29AAG.jpg, objectUrl=/article/show_article.do?id=05cf81954849, replyNumber=0, likeNumber=96, createdTime=2024-04-10, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=05cf81954849, moduleTitle=超40%患者6个月疾病无进展！周彩存教授：新一代ADC对乳腺癌、肺癌等有效 | 2024 AACR, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=05cf81954849)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2188778, encodeId=668e2188e78cf, content=<a href='/topic/show?id=370d8126914' target=_blank style='color:#2F92EE;'>#肝癌#</a> <a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a> <a href='/topic/show?id=85de5518160' target=_blank style='color:#2F92EE;'>#抗体偶联药物#</a> <a href='/topic/show?id=43c112234fc' target=_blank style='color:#2F92EE;'>#mRNA疫苗#</a> <a href='/topic/show?id=6e9011142e93' target=_blank style='color:#2F92EE;'>#蛋白降解靶向嵌合物#</a>, objectTitle=樊嘉院士等人发表重磅综述！晚期肝癌治疗有望迎来三类“新武器”！, objectType=article, longId=813994, objectId=139581399430, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-in-his-practice-with-a-digital-tablet-UWZKVBN.jpg, objectUrl=/article/show_article.do?id=139581399430, replyNumber=0, likeNumber=95, createdTime=2024-02-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=139581399430, moduleTitle=樊嘉院士等人发表重磅综述！晚期肝癌治疗有望迎来三类“新武器”！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=139581399430)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2182988, encodeId=f8e42182988b6, content=<a href='/topic/show?id=18c6256e1ba' target=_blank style='color:#2F92EE;'>#伊立替康#</a> <a href='/topic/show?id=85de5518160' target=_blank style='color:#2F92EE;'>#抗体偶联药物#</a> <a href='/topic/show?id=b5f71041887c' target=_blank style='color:#2F92EE;'>#ADC类药物#</a> <a href='/topic/show?id=cef011033832' target=_blank style='color:#2F92EE;'>#金盏花素#</a>, objectTitle=Nat Rev Clin Oncol：探索下一代抗体偶联药物（ADC）, objectType=article, longId=810303, objectId=34298103034d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20240118/98422350745646e6b023faa69c259d73.jpg, objectUrl=/article/show_article.do?id=34298103034d, replyNumber=0, likeNumber=101, createdTime=2024-01-21, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=加利福尼亚, moduleDTOList=[ModuleDTO(moduleId=34298103034d, moduleTitle=Nat Rev Clin Oncol：探索下一代抗体偶联药物（ADC）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34298103034d)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2169970, encodeId=e8b021699e072, content=<a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a> <a href='/topic/show?id=85de5518160' target=_blank style='color:#2F92EE;'>#抗体偶联药物#</a>, objectTitle=郭其森教授：ADC药物在晚期NSCLC中的研究进展, objectType=article, longId=801570, objectId=551c8015e04b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-writing-D3K6QME.jpg, objectUrl=/article/show_article.do?id=551c8015e04b, replyNumber=0, likeNumber=122, createdTime=2023-11-21, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=551c8015e04b, moduleTitle=郭其森教授：ADC药物在晚期NSCLC中的研究进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=551c8015e04b)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=885182, encodeId=fdbc88518269, content=<a href='/topic/show?id=85de5518160' target=_blank style='color:#2F92EE;'>#抗体偶联药物#</a>可能是未来的研发重点之一, objectTitle=AJOG：CD70抗体-药物偶联剂有望成为子宫平滑肌肉瘤的靶向药, objectType=article, longId=200203, objectId=3b7a200203e1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202093/1599112277054_2110107.PNG, objectUrl=/article/show_article.do?id=3b7a200203e1, replyNumber=0, likeNumber=214, createdTime=2020-09-14, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b7a200203e1, moduleTitle=AJOG：CD70抗体-药物偶联剂有望成为子宫平滑肌肉瘤的靶向药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b7a200203e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=885180, encodeId=d0af885180fb, content=<a href='/topic/show?id=85de5518160' target=_blank style='color:#2F92EE;'>#抗体偶联药物#</a>类药物，即ADC类药物，第一个上市的应该是<a href='/topic/show?id=bdeb1e018cc' target=_blank style='color:#2F92EE;'>#T-DM1#</a>，是罗氏的<a href='/topic/show?id=19951039032c' target=_blank style='color:#2F92EE;'>#赫赛莱#</a>，算是相当成功的，在晚期HER2+<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>中有很好的作用。这是2017年的一篇文章，现在是2020年，我们就可以看到，大量的ADC类药物在开发，很多都已上市或快上市了，未来会迎来一个小高潮。当然，对于抗体偶联药物类而言，可能仍然是过渡性的，<a href='/topic/show?id=2ad83e51258' target=_blank style='color:#2F92EE;'>#双特异性抗体#</a>，<a href='/topic/show?id=28eb1039047c' target=_blank style='color:#2F92EE;'>#三特异性抗体#</a>可能是真正的未来, objectTitle=Lancet Oncol：将单克隆抗体与杀伤细胞药物偶联（DS-8201）治疗晚期乳腺癌、胃食管癌的治疗效果和安全性。, objectType=article, longId=116484, objectId=912e1164841a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/webeditor/uploadfile/201710/20171017102626706.jpg, objectUrl=/article/show_article.do?id=912e1164841a, replyNumber=0, likeNumber=283, createdTime=2020-09-14, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=912e1164841a, moduleTitle=Lancet Oncol：将单克隆抗体与杀伤细胞药物偶联（DS-8201）治疗晚期乳腺癌、胃食管癌的治疗效果和安全性。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=912e1164841a)], followStatus=false, userIsMember=false, type=1, lengthMark=1)] 梅斯话题小助手

抗体偶联药物

2020-05-29

侠胆医心 (审核中...)

前往app查看评论内容

全文收起广泛期#小细胞肺癌#的标准一线治疗是铂类与#依托泊苷#，联合PD-L1抑制剂。二线治疗则是#拓扑替康#和#鲁比奈克汀#。二线治疗的中位无进展生存时间为3.5个月。 #抗体偶联药物##ABBV-011#是针对SEZ6的抗体偶联药，总体的治疗缓解率为25%，也就是25%的患者肿瘤病灶缩小超过30%，中位缓解持续时间为4.2个月，中位无进展生存时间为3.5个月。从这里来看ABBV-011仍然没有什么突破性进展，后续2，3期临床还能否达到这样的效果，还不好说。总的一句话，小细胞肺癌，真的太难太难。

治疗小细胞肺癌的抗体偶联药ABBV-011，首次人体临床试验结果公布了！

8小时前发表于威斯康星

梅斯管理员 (审核中...)

前往app查看评论内容

#抗体偶联药物# #双特异性抗体偶联药物#

引领未来：双抗ADC的前沿进展

2024-12-03发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#抗体偶联药物#

【今日分享】抗体偶联药物分段生产试点注册申报技术要求

2024-11-13发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#抗体偶联药物# #ADC# #有效载荷释放#

ADC连接子的集成设计

2024-10-06发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#抗体偶联药物# #靶抗原#

ADC设计中的靶抗原选择

2024-09-22发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#抗体偶联药物# #DP303c#

靶向HER2的抗体偶联药DP303c临床治疗效果首次公布，近70%的实体瘤病情得以控制！

2024-09-20发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#抗体偶联药物# #ESMO 2024#

2024ESMO | 新型B7H3抗体偶联药物初次亮相即创多个瘤肿后线疗效新高：张力、赵洪云教授团队口头汇报YL-201初步结果

2024-09-19发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#宫颈癌# #抗体偶联药物# #Tivdak#

NEJM：4倍缓解几率！创新ADC疗法延长宫颈癌患者生存期

2024-07-30发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#联合疗法# #抗体偶联药物# #免疫疗法#

ADC的联合治疗之路

2024-07-23发表于上海

梅斯管理员 (审核中...)